Innate Pharma has dosed the first patient in the Phase II MATISSE clinical trial of IPH5201 along with durvalumab and chemotherapy to treat non-small cell lung cancer (NSCLC).

The single-arm, multi-centre study will evaluate neoadjuvant and adjuvant treatment with the anti-CD39 blocking monoclonal antibody IPH5201 combined with durvalumab and chemotherapy in treatment-naïve patients with resectable early-stage NSCLC.

Assessing the antitumour activity of neoadjuvant treatment based on pathological complete response (pCR) and safety is the primary objective of the study.

Innate Pharma chief medical officer Joyson Karakunnel said: “We are pleased to announce the dosing of the first patient in this Phase II study conducted in collaboration with our partner AstraZeneca.

“If this combination shows relevant anti-tumour activity while remaining well tolerated, as observed in the previous Phase I study, it will be a major step in the development of IPH5201 in this indication.”

Innate is conducting the trial and shares the study costs with AstraZeneca, which is responsible for supplying the drugs for the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A multi-term deal, including an option agreement for IPH5201, was signed between both companies in October 2018.

AstraZeneca made a $50m upfront payment to Innate for the option to the exclusive license to co-develop and co-commercialise the antibody.

It also paid high-single to double-digit tiered royalties. The deal also included around $825m opt-in payments, as well as commercial and development milestones.

As part of the option agreement, Innate agreed to retain the right to receive profit sharing within the EU.